A treatment that could protect premature babies from brain damage showed promise in a recent study in Sweden. Using a ...

WVE-007, an INHBE GalNAc-siRNA for obesity designed to drive fat loss while preserving muscle mass, achieved dose-dependent, mean reductions of ...

Oral presentation of biomarker data shows RP1 plus nivolumab reverses multiple resistance mechanisms to PD-1 blockade in advanced melanoma following definitive anti-PD-1 failureWOBURN, Mass., Nov. 07, ...

Your annual reminder that the slushy constituent services funds are available to help with bills, rent, and plastic leis, apparently.

Leptomeningeal metastases disease session features novel treatments in the horizon, REYOBIQ™ and ReSPECT-LM, and future directions and needsHOUSTON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics ...

WVE-007, an INHBE GalNAc-siRNA for obesity designed to drive fat loss while preserving muscle mass, achieved dose-dependent, mean reductions of Activin E of up to 85% in INLIGHT clinical trial, exceed ...